Anti-proliferative activity and mechanism of action of titanocene dichloride

British Journal of Cancer

Volumn 77, Issue 12, 1998, Pages 2088-2097

  Christodoulou, C V ^a   Eliopoulos, A G ^a   Young, L S ^a   Hodgkins, L ^a   Ferry, D R ^a   Kerr, D J ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

Organometallic compound; Ovarian carcinoma cells; Platinum resistance; Titanocene dichloride

Indexed keywords

DNA; FLUOROURACIL; PROTEIN BCL 2; PROTEIN P53; TITANOCENE DICHLORIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ATOMIC ABSORPTION SPECTROMETRY; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; CONTROLLED STUDY; DNA ADDUCT; DNA DAMAGE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SYNTHESIS; GENE MUTATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL;

EID: 0031779573     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.352     Document Type: Article

References (39)

1. Advanced Ovarain Cancer Trialists Group (1991) Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. Br Med J 303: 884-893
2. Andrews PA and Howell SB (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells (Cold Spring Harbor) 2: 35-43
3. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR, Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC and Ozols RF (1987) Characterization of a cis-platinum resistant ovarian cell line and its use in evaluation of platinum analogues. Cancer Res 47: 414-418
4. Berenbaum MC (1981) Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 35: 264-335
5. Calvert AH, Newell DR and Tilby MJ (1995) Cisplatin and analogues: discovery, mechanism of action and clinical pharmacology. In Oxford Textbook of Oncology, Pecham M, Pinedo HM and Veronesi U. (eds), pp. 552-565. Oxford University Press: New York
6. Dive C and Hickman JA (1991) Drug-target interactions: only the first step in the commitment to programmed cell death. Br J Cancer 64: 192-196
7. Dive C and Wyllie AH (1993) Apoptosis and cancer chemotherapy. In Cancer Chemotherapy, Hickman JA and Tritton TR. (eds), pp. 21-56. Blackwell Scientific Publications: Oxford
8. Dorr RT and Von Hoff DD (1993) Oxaliplatin. In Cancer Chemotherapy Handbook, Appleton and Lange (eds), pp. 758-761, Norwalk, CT
9. Eisenhauer E, Swerton K, Sturgeon J, Fine S, O'Reilly S and Canetta R (1990) Carboplatin therapy for recurrent ovarian carcinoma: National Cancer Institute of Canada experience and a review of the literature. In Carboplatin: Current Perspectives and Future Directions, Bunn P, Canetta R, Ozols R and Rozencweig M. (eds), pp. 133-140. WB Saunders: Philadelphia
10. Eliopoulos AG and Spandidos DA (1994) Altered binding of the AP-1 protein on a negative regulatory element of c-myc is correlated with the progression of the malignancy of the lung and may contribute to c-myc expression. Oncol Rep 1: 139-143
11. Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC and Young L (1995) The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and bcl-2. Oncogene 11: 1217-1228
12. Eliopoulos AG, Dawson CW, Mosialos G, Floettmann JE, Rowe M, Armitage RJ, Dawson J, Zapata JM, Kerr DJ, Wakelam MJO, Reed JC, Kieff E and Young LS (1996) CD40-induced growth inhibition in epithelial cells is mimicked by EBV-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 13: 2243-2254
13. Gorczyca W, Gong J, Ardelt B, Traganos F and Darzynkiewicz Z (1993) The cell cycle related differences in susceptibility of HL60 cells to apoptosis induced by various antitumour agents. Cancer Res 53: 3186-3192
14. Gore ME, Fryatt I, Wiltshaw E, Dawson T, Robinson BA and Calvert AH (1989) Cisplatin/carboplatin cross-resistance in ovarian cancer. Br J Cancer 60: 767-769
15. Hainaut P (1995) The tumour supressor protein p53, a receptor to genotoxic stress that controls cell growth and survival. Curr Opin Oncol 7: 76-82
16. Harstrick A, Schmoll HJ, Sass G, Poliwoda H and Rustum Y (1993) Activity of a novel metal compound, titanocene dichloride in cisplatin and doxorubicin resistant human ovarian carcinoma cell lines. Eur J Cancer 29: 1000-1002
17. Herod JJO, Eliopoulos AG, Warwick J, Niedobitek G, Young ES and Kerr DJ (1996) The prognostic significance of bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 56: 2178-2184
18. Kastan MB, Onyekwere O, Sibransky D, Vogelstein B and Craig RW (1991) Participation of p53 protein in the cellular response to DNA damage. Cancer Res 51: 6304-6311
19. Kelland LR, Mistry P, Abel G, Loh SY, O'Neil F, Murrer BA and Harrap KR (1992) Mechanism-related circumvention of acquired cis-diamminedichloroplatinum(II) resistance using two pairs of human ovarian carcinoma cell lines by ammine/amine platinum(IV) dicarboxylates. Cancer Res 52: 3857-3864
20. Köpf-Maier P (1987) Tumor inhibition by titanocene complexes: influence upon two xenografted human lung carcinomas. J Cancer Res Clin Oncol 113: 342-348
21. Köpf-Maier P (1989a) The antitumor activity of transition and main group metal cyclopentadienyl compexes. In Progress in Clinical Biochemistry and Medicine, Vol. 10, pp. 152-184. Springer-Verlag: Berlin
22. Köpf-Maier P (1989b) Tumor inhibition by titanocene complexes: influence on xenografted human adenocarcinomas of the gastrointestinal tract. Cancer Chemother Pharmacol 24: 23-27
23. 2 on renal structure. Toxicology 38: 81-90
24. Köpf-Maier P and Geralch S (1986) Pattern of toxicity by titanocene dichloride in mice. Hematologic parameters. Anticancer Res 6: 227-240
25. Köpf-Maier P and Köpf H (1988) Antitumor cyclopentadienyl metal-complexes: current status and recent pharmacological results. In Metal-based Anti-tumour Drugs, Gielen MF. (eds.), pp. 55-102. Freund Publishing House: London
26. Köpf-Maier P, Moorman A and Köpf H (1985) Activity of titanocene dihalides against human colon carcinoma heterotransplanted to athymic mice. Eur J Cancer Clin Oncol 21: 853-857
27. Köpl-Maier P, Brauckle U and Heussler A (1988) Organ distribution and pharmacokinetics of titanium after treatment with titanocene dichloride. Toxicology 51: 291-298
28. Kortel A, Schmol HJ, Scheulen ME, Gründel O, Harstrick A, Knoche M, Fels LM, Bach F, Baugmart J, Saß G, Thiel E and Berdel WE (1996) Clinical phase I and Pharmacokinetic Study of Titanocene Dichloride in Patients with Advanced Solid Tumors. ASCO 356: 38
29. Lane DP (1992) p53, guardian of the genome. Nature 358: 15-16
30. Levi F, Machover D, Marty M, Diazrubio E, DcGramont A, Garufi C, Itzaki M, Cvitkovic E, Bensmaine MA, Brienza S and Misset JL (1995) Oxaliplatin - summary of results in advanced colorectal cancer (ACC). Eur J Cancer 31A: 738
31. Martin SJ and Green DR (1994) Apoptosis as a goal of cancer therapy. Curr Opin Oncol 6: 616-621
32. Masuda H, Tanaka T, Matsuda H and Kusaba I (1990) Increased removal of DNA-bound platinum in a human ovarian cancer cell line resistant to cis-diamminedichloroplatinum(II). Cancer Res 50: 1863-1866
33. Mathe G, Kidani Y and Segiguchi M (1989) Oxaloplatinum or L-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cisplutinum and carhoplalinum. Biomed Pharmacother 43: 237-250
34. Mosmann T (1983) Rapid colometric assay for cellular growth and survival. J Immunol Methods 65: 55-63
35. Pendyala L and Creaven PJ (1993) In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 53: 5970-5976
36. Roberts JJ, Knox RJ, Friedlos F and Lydall DA (1986) DNA as the target for the cytotoxic and anti-tumour action of platinum co-ordinaton complexes: comparative in vitro and in vivo studies of cisplatin and carboplatin. In Biochemical Mechanisms of Platinum Antitumour Druigs, McBrien DCH and Slater TF (eds), pp. 29-64. IRL Press: Oxford
37. Rosenberg B, VanCamp L, Trosko JH and Mansour VH (1969) Platinum compounds: a new class of potent antitumor agents. Nature 222: 385-186
38. Sambrook J, Fritsch EH and Maniatis T (1989) Molecular Cloning - a Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor NY. pp 9.4-9.60
39. Tashiro T, Kawada Y, Sakurai Y and Kidani Y (1989) Antitumor activity of a new platinum complex, oxalato (trans-1,2-diaminocyclohexane) platinum(11): new experimental data. Biomed Pharmacother 43: 251-260